

2017-2022 Global and Japan RNAi for Therapeutic Market Analysis Report

https://marketpublishers.com/r/211AC3EEFA3EN.html

Date: August 2017

Pages: 127

Price: US\$ 3,085.00 (Single User License)

ID: 211AC3EEFA3EN

Abstracts

The global RNAi for Therapeutic market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the RNAi for Therapeutic market's development status and future trend in the global and Japan. It splits RNAi for Therapeutic market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include

Alnylam Pharmaceuticals (USA)

Arbutus Biopharma (Tekmira) (Canada)

Arrowhead Research (USA)

Dicerna Pharmaceuticals (USA)

Mirna Therapeutics (USA)

Quark Pharmaceuticals (Israel)



RXi Pharmaceuticals (USA)

Silence Therapeutics (Germany)

Benitec Biopharma (Australia)

miRagen Therapeutics (USA)

Sylentis (Spain)

Gradalis (USA)

Sirnaomics (USA)

Silenseed (Israel)

Arcturus Therapeutics (USA)

Arcturus Therapeutics (USA)

Ariz Biopharma (USA)

GeneCopoeia (USA)

Ascletis Pharmaceuticals (USA)

Celsion Corporation (USA)

Astellas Pharma (USA)

AstraZeneca (UK)

BioSpring (Vietnam)

Calando Pharmaceuticals (USA)

Celgene (USA)

Bayer Heathcare (USA)



E	Biogazelle (Belgium)			
(CombiMatrix (USA)			
(Creative Animodel (USA)			
E	Ensysce Biosciences (USA)			
Geographically, this report splits the Global market into the following regions:				
A	Asia Pacific			
	Japan			
		Tokyo		
		Yokohama		
		Osaka		
		Nagoya		
		Others		
	China			
	Korea			
	India			
	Others			
E	Europe			
	France			

Germany



United Kingdom		
Italy		
Russia		
Others		
North America		
United States		
Canada		
Latin America		
Brazil		
Mexico		
Others		
Southeast Asia		
Singapore		
Malaysia		
Vietnam		
Myanmar		
Thailand		
Indonesia		
Philippines		



Others			
Middle East & Africa			
Saudi Arabia			
Iran			
UAE			
Turkey			
Israel			
Egypt			
South Africa			
Others			
on the basis of product, the RNAi for Therapeutic market is primarily split into			
By Technology			
siRNA			
miRNA			
shRNA			
By Molecular Form			
Single Chain			
Double Chain			



Cancer

Cardiovascular

HBV

Other



Contents

2017-2022 GLOBAL AND JAPAN RNAI FOR THERAPEUTIC MARKET ANALYSIS REPORT

1 RNAI FOR THERAPEUTIC OVERVIEW

- 1.1 Product Overview and Scope of RNAi for Therapeutic
- 1.2 Global and Japan RNAi for Therapeutic Market by Applications/End Users
- 1.2.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
- 1.2.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Applications (2012-2017)
- 1.2.1.2 Japan RNAi for Therapeutic Sales Growth Rate (%) by Applications (2012-2017)
 - 1.2.1.3 Market Drivers and Opportunities
- 1.2.2 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
 - 1.2.3 Global RNAi for Therapeutic Sales by Application (2012-2017)
- 1.2.3.1 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Applications (2012-2017)
- 1.2.3.2 Global RNAi for Therapeutic Sales Growth Rate (%) by Applications (2012-2017)
 - 1.2.3.3 Market Drivers and Opportunities
- 1.2.4 Global RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
 - 1.2.5 Cancer
 - 1.2.6 Cardiovascular
 - 1.2.7 HBV
 - 1.2.8 Other
- Global and Japan Market Size (Sales and Revenue) of RNAi for Therapeutic
 (2012-2017)
 - 1.3.1 Japan Market Size (Sales and Revenue) of RNAi for Therapeutic (2012-2017)
 - 1.3.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) (2012-2017)
- 1.3.1.2 Japan RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2012-2017)
 - 1.3.2 Global Market Size (Sales and Revenue) of RNAi for Therapeutic (2012-2017)
 - 1.3.2.1 Global RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) (2012-2017)
 - 1.3.2.2 Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate



(2012-2017)

- 1.4 Global and Japan Classification of RNAi for Therapeutic by Technology
- 1.4.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Technology (2012-2017)
- 1.4.2 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Technology (2012-2017)
- 1.4.3 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share by Technology (2012-2017)
- 1.4.4 Global RNAi for Therapeutic Revenue (Million USD) and Market Share by Technology (2012-2017)
 - 1.4.5 Japan RNAi for Therapeutic Price (USD/Pcs) by Technology (2012-2017)
 - 1.4.6 Global RNAi for Therapeutic Price (USD/Pcs) by Technology (2012-2017)
 - 1.4.7 Japan RNAi for Therapeutic Sales Growth Rate (%) by Technology (2012-2017)
 - 1.4.8 Global RNAi for Therapeutic Sales Growth Rate (%) by Technology (2012-2017)
 - 1.4.9 siRNA
 - 1.4.10 miRNA
 - 1.4.11 shRNA
- 1.5 Global and Japan Classification of RNAi for Therapeutic by Molecular Form
- 1.5.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Molecular Form (2012-2017)
- 1.5.2 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Molecular Form (2012-2017)
- 1.5.3 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share by Molecular Form (2012-2017)
- 1.5.4 Global RNAi for Therapeutic Revenue (Million USD) and Market Share by Molecular Form (2012-2017)
 - 1.5.5 Japan RNAi for Therapeutic Price (USD/Pcs) by Molecular Form (2012-2017)
 - 1.5.6 Global RNAi for Therapeutic Price (USD/Pcs) by Molecular Form (2012-2017)
- 1.5.7 Japan RNAi for Therapeutic Sales Growth Rate (%) by Molecular Form (2012-2017)
- 1.5.8 Global RNAi for Therapeutic Sales Growth Rate (%) by Molecular Form (2012-2017)
 - 1.5.9 Single Chain
 - 1.5.10 Double Chain

2 GLOBAL AND JAPAN RNAI FOR THERAPEUTIC MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan RNAi for Therapeutic Market Competition by Players/Manufacturers



- 2.1.1 Japan RNAi for Therapeutic Sales and Market Share of Key Players/Manufacturers (2012-2017)
- 2.1.2 Japan RNAi for Therapeutic Revenue and Share by Players/Manufacturers (2012-2017)
- 2.1.3 Japan RNAi for Therapeutic Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
 - 2.1.4 Japan RNAi for Therapeutic Market Competitive Situation and Trends
 - 2.1.4.1 Japan RNAi for Therapeutic Market Concentration Rate
- 2.1.4.2 Japan RNAi for Therapeutic Market Share of Top 3 and Top 5 Players/Manufacturers
 - 2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
- 2.1.5 Japan Players/Manufacturers RNAi for Therapeutic Manufacturing Base Distribution, Sales Area, Product Types
- 2.2 Global RNAi for Therapeutic Market Competition by Players/Manufacturers
- 2.2.1 Global RNAi for Therapeutic Sales and Market Share of Key Players/Manufacturers (2012-2017)
- 2.2.2 Global RNAi for Therapeutic Revenue and Share by Players/Manufacturers (2012-2017)
- 2.2.3 Global RNAi for Therapeutic Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
 - 2.2.4 Global RNAi for Therapeutic Market Competitive Situation and Trends
 - 2.2.4.1 Global RNAi for Therapeutic Market Concentration Rate
- 2.2.4.2 Global RNAi for Therapeutic Market Share of Top 3 and Top 5 Players/Manufacturers
 - 2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
- 2.2.5 Global Players/Manufacturers RNAi for Therapeutic Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN RNAI FOR THERAPEUTIC SALES AND REVENUE BY REGIONS (2012-2017)

- 3.1 Asia Pacific RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
 - 3.1.1 Japan RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.1.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.1.1.2 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.1.1.3 Japan RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.1.2 China RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.1.2.1 China RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)



- 3.1.2.2 China RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.1.2.3 China RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.1.3 Korea RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.1.3.1 Korea RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.1.3.2 Korea RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.1.3.3 Korea RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.1.4 India RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.1.4.1 India RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.1.4.2 India RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.1.4.3 India RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.1.5 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.1.5.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.1.5.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.1.5.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.2 Europe RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
 - 3.2.1 France RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.2.1.1 France RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.1.2 France RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.2.1.3 France RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.2.2 Germany RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.2.2.1 Germany RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.2.2 Germany RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.2.2.3 Germany RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.2.3 United Kingdom RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.2.3.1 United Kingdom RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.3.2 United Kingdom RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.2.3.3 United Kingdom RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.2.4 Italy RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.2.4.1 Italy RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.4.2 Italy RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)



- 3.2.4.3 Italy RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.2.5 Russia RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.2.5.1 Russia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.5.2 Russia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.2.5.3 Russia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.2.6 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.2.6.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.2.6.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.2.6.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.3 North America RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
 - 3.3.1 United States RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.3.1.1 United States RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.3.1.2 United States RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.3.1.3 United States RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.3.2 Canada RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.3.2.1 Canada RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.3.2.2 Canada RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.3.2.3 Canada RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.4 Latin America RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
- 3.4.1 Brazil RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.4.1.1 Brazil RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.4.1.2 Brazil RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.4.1.3 Brazil RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.4.2 Mexico RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.4.2.1 Mexico RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.4.2.2 Mexico RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.4.2.3 Mexico RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.4.3 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.4.3.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.4.3.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.4.3.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)



- 3.5 Southeast Asia RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
 - 3.5.1 Singapore RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.1.1 Singapore RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.1.2 Singapore RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.1.3 Singapore RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.2 Malaysia RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.2.1 Malaysia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.2.2 Malaysia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.2.3 Malaysia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.3 Vietnam RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.3.1 Vietnam RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.3.2 Vietnam RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.3.3 Vietnam RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.4 Myanmar RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.4.1 Myanmar RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.4.2 Myanmar RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.4.3 Myanmar RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.5 Thailand RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.5.1 Thailand RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.5.2 Thailand RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.5.3 Thailand RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.6 Indonesia RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.6.1 Indonesia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.6.2 Indonesia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.6.3 Indonesia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.5.7 Philippines RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.5.7.1 Philippines RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.5.7.2 Philippines RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.7.3 Philippines RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.5.8 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.5.8.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)



- 3.5.8.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.8.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.6 Middle East & Africa RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
 - 3.6.1 Saudi Arabia RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.6.1.1 Saudi Arabia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.1.2 Saudi Arabia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.1.3 Saudi Arabia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
- 3.6.2 Iran RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.2.1 Iran RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.2.2 Iran RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.2.3 Iran RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.3 UAE RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.3.1 UAE RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.3.2 UAE RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.3.3 UAE RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.4 Turkey RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.4.1 Turkey RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.4.2 Turkey RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.4.3 Turkey RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.5 Israel RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.5.1 Israel RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.5.2 Israel RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.5.3 Israel RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.6 Egypt RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.6.1 Egypt RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.6.2 Egypt RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.6.3 Egypt RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.7 South Africa RNAi for Therapeutic Sales and Revenue (2012-2017)
- 3.6.7.1 South Africa RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)



- 3.6.7.2 South Africa RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.7.3 South Africa RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
 - 3.6.8 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
 - 3.6.8.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
- 3.6.8.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
 - 3.6.8.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)

4 GLOBAL AND JAPAN RNAI FOR THERAPEUTIC PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

- 4.1 Alnylam Pharmaceuticals (USA)
 - 4.1.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.1.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.1.2.1 Product A
 - 4.1.2.2 Product B
- 4.1.3 Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.1.4 Main Business/Business Overview
- 4.2 Arbutus Biopharma (Tekmira) (Canada)
 - 4.2.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.2.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.2.2.1 Product A
 - 4.2.2.2 Product B
- 4.2.3 Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.2.4 Main Business/Business Overview
- 4.3 Arrowhead Research (USA)
 - 4.3.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.3.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.3.2.1 Product A
 - 4.3.2.2 Product B
- 4.3.3 Arrowhead Research (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.3.4 Main Business/Business Overview
- 4.4 Dicerna Pharmaceuticals (USA)
- 4.4.1 Company Basic Information, Manufacturing Base and Competitors
- 4.4.2 RNAi for Therapeutic Product Category, Application and Specification



- 4.4.2.1 Product A
- 4.4.2.2 Product B
- 4.4.3 Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.4.4 Main Business/Business Overview
- 4.5 Mirna Therapeutics (USA)
 - 4.5.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.5.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.5.2.1 Product A
 - 4.5.2.2 Product B
- 4.5.3 Mirna Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.5.4 Main Business/Business Overview
- 4.6 Quark Pharmaceuticals (Israel)
 - 4.6.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.6.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.6.2.1 Product A
 - 4.6.2.2 Product B
- 4.6.3 Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
- 4.6.4 Main Business/Business Overview
- 4.7 RXi Pharmaceuticals (USA)
 - 4.7.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.7.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.7.2.1 Product A
 - 4.7.2.2 Product B
- 4.7.3 RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
- 4.7.4 Main Business/Business Overview
- 4.8 Silence Therapeutics (Germany)
 - 4.8.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.8.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.8.2.1 Product A
 - 4.8.2.2 Product B
- 4.8.3 Silence Therapeutics (Germany) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.8.4 Main Business/Business Overview
- 4.9 Benitec Biopharma (Australia)
 - 4.9.1 Company Basic Information, Manufacturing Base and Competitors



- 4.9.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.9.2.1 Product A
 - 4.9.2.2 Product B
- 4.9.3 Benitec Biopharma (Australia) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.9.4 Main Business/Business Overview
- 4.10 miRagen Therapeutics (USA)
 - 4.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.10.2 RNAi for Therapeutic Product Category, Application and Specification
 - 4.10.2.1 Product A
 - 4.10.2.2 Product B
- 4.10.3 miRagen Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
 - 4.10.4 Main Business/Business Overview
- 4.11 Sylentis (Spain)
- 4.12 Gradalis (USA)
- 4.13 Sirnaomics (USA)
- 4.14 Silenseed (Israel)
- 4.15 Arcturus Therapeutics (USA)
- 4.16 Arcturus Therapeutics (USA)
- 4.17 Ariz Biopharma (USA)
- 4.18 GeneCopoeia (USA)
- 4.19 Ascletis Pharmaceuticals (USA)
- 4.20 Celsion Corporation (USA)
- 4.21 Astellas Pharma (USA)
- 4.22 AstraZeneca (UK)
- 4.23 BioSpring (Vietnam)
- 4.24 Calando Pharmaceuticals (USA)
- 4.25 Celgene (USA)
- 4.26 Bayer Heathcare (USA)
- 4.27 Biogazelle (Belgium)
- 4.28 CombiMatrix (USA)
- 4.29 Creative Animodel (USA)
- 4.30 Ensysce Biosciences (USA)

5 RNAI FOR THERAPEUTIC MANUFACTURING COST ANALYSIS

- 5.1 RNAi for Therapeutic Key Raw Materials Analysis
 - 5.1.1 Key Raw Materials



- 5.1.2 Price Trend of Key Raw Materials
- 5.1.3 Key Suppliers of Raw Materials
- 5.1.4 Market Concentration Rate of Raw Materials
- 5.2 Proportion of Manufacturing Cost Structure
 - 5.2.1 Raw Materials
 - 5.2.2 Labor Cost
 - 5.2.3 Manufacturing Expenses
- 5.3 Manufacturing Process Analysis of RNAi for Therapeutic

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 6.1 RNAi for Therapeutic Industrial Chain Analysis
- 6.2 Upstream Raw Materials Sourcing
- 6.3 Raw Materials Sources of RNAi for Therapeutic Major Players/Manufacturers in 2016
- 6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 7.1 Marketing Channel
 - 7.1.1 Direct Marketing
 - 7.1.2 Indirect Marketing
 - 7.1.3 Marketing Channel Development Trend
- 7.2 Market Positioning
 - 7.2.1 Pricing Strategy
 - 7.2.2 Brand Strategy
 - 7.2.3 Target Client
- 7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

- 8.1 Technology Progress/Risk
 - 8.1.1 Substitutes Threat
 - 8.1.2 Technology Progress in Related Industry
- 8.2 Consumer Needs/Customer Preference Change
- 8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN RNAI FOR THERAPEUTIC MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)



- 9.1 Global and Japan RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
- 9.2 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
 - 9.2.1 by Technology
 - 9.2.2 by Molecular Form
- 9.3 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022)
- 9.4 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

- 11.1 Methodology/Research Approach
 - 11.1.1 Research Programs/Design
 - 11.1.2 Market Size Estimation
 - 11.1.3 Market Breakdown and Data Triangulation
- 11.2 Data Source
 - 11.2.1 Secondary Sources
 - 11.2.2 Primary Sources
- 11.3 Disclaimer
- 11.4 Author List



List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of RNAi for Therapeutic

Table Japan RNAi for Therapeutic Sales (Million Units) Comparison by Applications (2012-2017)

Figure Japan Sales Market Share (%) of RNAi for Therapeutic by Applications in 2016 Table Global RNAi for Therapeutic Sales (Million Units) Comparison by Applications (2012-2017)

Figure Global Sales Market Share (%) of RNAi for Therapeutic by Applications in 2016 Figure Cancer Examples

Table Key Downstream Customer in Cancer

Figure Cardiovascular Examples

Table Key Downstream Customer in Cardiovascular

Figure HBV Examples

Table Key Downstream Customer in HBV

Figure Other Examples

Table Key Downstream Customer in Other

Figure siRNA Product Picture

Figure miRNA Product Picture

Figure shRNA Product Picture

Figure Single Chain Product Picture

Figure Double Chain Product Picture

Table Alnylam Pharmaceuticals (USA) Basic Information List

Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Arbutus Biopharma (Tekmira) (Canada) Basic Information List

Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales (K Pcs),

Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales Market



Share (%) in Japan (2012-2017)

Figure Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Arrowhead Research (USA) Basic Information List

Table Arrowhead Research (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Arrowhead Research (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Arrowhead Research (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Arrowhead Research (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Dicerna Pharmaceuticals (USA) Basic Information List

Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Mirna Therapeutics (USA) Basic Information List

Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Mirna Therapeutics (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Quark Pharmaceuticals (Israel) Basic Information List

Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Quark Pharmaceuticals (Israel) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)



Table RXi Pharmaceuticals (USA) Basic Information List

Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure RXi Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Silence Therapeutics (Germany) Basic Information List

Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Silence Therapeutics (Germany) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Benitec Biopharma (Australia) Basic Information List

Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure Benitec Biopharma (Australia) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table miRagen Therapeutics (USA) Basic Information List

Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)

Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)

Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)

Figure miRagen Therapeutics (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)

Table Sylentis (Spain) Basic Information List

Table Gradalis (USA) Basic Information List

Table Sirnaomics (USA) Basic Information List



Table Silenseed (Israel) Basic Information List

Table Arcturus Therapeutics (USA) Basic Information List

Table Arcturus Therapeutics (USA) Basic Information List

Table Ariz Biopharma (USA) Basic Information List

Table GeneCopoeia (USA) Basic Information List

Table Ascletis Pharmaceuticals (USA) Basic Information List

Table Celsion Corporation (USA) Basic Information List

Table Astellas Pharma (USA) Basic Information List

Table AstraZeneca (UK) Basic Information List

Table BioSpring (Vietnam) Basic Information List

Table Calando Pharmaceuticals (USA) Basic Information List

Table Celgene (USA) Basic Information List

Table Bayer Heathcare (USA) Basic Information List

Table Biogazelle (Belgium) Basic Information List

Table CombiMatrix (USA) Basic Information List

Table Creative Animodel (USA) Basic Information List

Table Ensysce Biosciences (USA) Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of RNAi for Therapeutic

Figure Manufacturing Process Analysis of RNAi for Therapeutic

Figure RNAi for Therapeutic Industrial Chain Analysis

Table Raw Materials Sources of RNAi for Therapeutic Major Players/Manufacturers in 2016

Table Major Buyers of RNAi for Therapeutic

Table Distributors/Traders List

Figure Japan RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)

Figure Japan RNAi for Therapeutic Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Japan RNAi for Therapeutic Price (USD/Pcs) Trend Forecast (2017-2022)

Figure Global RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)

Figure Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Global RNAi for Therapeutic Price (USD/Pcs) Trend Forecast (2017-2022)

Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)

Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)



Figure Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022) Figure Global RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022) Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Type in 2017

Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Type in 2017

Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022) Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Application (2017-2022)

Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Application in 2017

Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022) Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Application (2017-2022)

Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Application in 2017

Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022) Table Japan RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)

Figure Japan RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)

Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022) Table Global RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)

Figure Global RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources



I would like to order

Product name: 2017-2022 Global and Japan RNAi for Therapeutic Market Analysis Report

Product link: https://marketpublishers.com/r/211AC3EEFA3EN.html

Price: US\$ 3,085.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/211AC3EEFA3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970